Leukotriene receptor antagonists as add-on therapy for adults with asthma

Thorax

Volumn 58, Issue 3, 2003, Pages 190-192

  Thomson, N C ^a   Shepherd, M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; SALMETEROL; ZAFIRLUKAST;

ALGORITHM; ASTHMA; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DIGESTIVE SYSTEM DISEASE; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEADACHE; HUMAN; LUNG FUNCTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SIDE EFFECT; UNITED KINGDOM;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG THERAPY, COMBINATION; HUMANS; LEUKOTRIENE ANTAGONISTS; PRACTICE GUIDELINES;

EID: 0037340066     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.58.3.190     Document Type: Review

References (28)

1. Walsh L, Wong C, Cooper S, et al. Morbidity from asthma in relation to regular treatment: a community based study. Thorax 1999;54:296-300.
2. Rabe KF, Vermiere PA, Soriano JB, et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000;16:802-7.
3. Strachan DP. Defining unmet need. Asthma J 2000;5:137-40.
4. Hoskins G, McCowan C, Neville RG, et al. Risk factors and costs associated with an asthma attack. Thorax 2000;55:19-24.
5. Serra-Batlles J, Plaza V, Morejon E, et al. Costs of asthma according to the degree of severity. Eur Respir J 1998;12:1322-6.
6. British Thoracic Society. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997;52(Suppl 1):S1-21.
7. British Thoracic Society/Scottish Intercollegiate Guideline Network (BTS/SIGN). British guideline on the management of asthma. Thorax 2003;58(Suppl I):i1-94.
8. National Institutes of Health. Highlights of the Expert Panel Report II: Guidelines for the diagnosis and management of asthma. NIH publication no. 97-4051. Bethesda, MD: National Institutes of Health, 1997.
9. National Institutes of Health, National Heart, Lung and Blood Institute. Global initiative for asthma. Global strategy for asthma management and prevention. Publication no. 95-3659. Bethesda, MD: NHLBI/WHO Workshop Report, 1995.
10. Scottish Intercollegiate Guideline Network (SIGN). SIGN 50: a guideline developer's handbook. SIGN publication no. 50. Edinburgh: SIGN, 2002.
11. Vaquerizo MJ, Casan P, Castillo J, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003;58:204-10.
12. Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;58:211-6.
13. Laviolette M, Malmström K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999;160:1862-8.
14. Löfdahl C-G, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene-receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999;319:87-90
15. Tohda Y, Fujimuri M, Taniguchi H, et al. Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. Clin Exp Allergy 2002;32:1180-6.
16. Virchow JC, Prasse A, Naya I, et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000;162:578-85.
17. Ducharme F, Hicks G, Kakuma R. Addition of anti-leukotriene agents compared to inhaled corticosteroids for chronic asthma (Cochrane Revieww). In: The Cochrane Library. Issue 1. Oxford: Update Software, 2002.
18. Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999;103:1075-80.
19. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol. 2000;106:1088-95.
20. Gershman NH, Wong HH, Liu JT, et al. Low and high-dose fluticasone propionate in asthma: effects during and after treatment. Eur Respir J 2000;15:11-8.
21. Holt S, Suder A, Weatherall M, et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001;323:253-6.
22. Bousquet J, Ben-Joseph R, Messonnier M, et al. A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistant asthma. Clin Ther 2002;24:1-20.
23. Adams N, Bestall J, Jones P. Inhaled beclomethasone at different doses for long term asthma (Cochrane Review). In: The Cochrane Library. Issue 1. Oxford: Update Software, 2001.
24. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001;357:1991-2.
25. Stirling RG, Chung KF. Leukotriene antagonists and Churg-Strauss syndrome: the smoking gun. Thorax 1999;54:865-6.
26. Tuggery JM, Hosker HSR. Churg-Strauss syndrome associated with montelukast therapy. Thorax 2000;55:805-6.
27. Chalmers GW, Macleod KJ, Little SA, et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002;57:226-30.
28. Tattersfield AE, Harrison TW. Step 3 of the asthma guidelines. Thorax 1999;54:753-4.